(Total Views: 814)
Posted On: 06/20/2020 2:09:12 AM
Post# of 72440
My take is that the NYT article is being spun by the criminal soft bashers as a very feeble false narrative. Take a step back and put yourself in the current administration’s shoes. Do you put all of your eggs in the vaccine basket that won’t be available until 2021 AFTER the election or do you fast track a treatment that basically kills the virus on contact? This treatment could be approved BEFORE the election to make CV19 considerably less threatening and allowing people to feel comfortable going to restaurants, airplanes, school etc.. basically getting back to normalcy and getting the economy back on track. Also note from the article:
“But the shift in strategy also shows that the administration is backing away from the relatively modest funding it has provided so far for treatments that address the severe lung ailments, while CONTINUING support for ANTIVIRAL therapies that could treat people earlier in the course of the disease.”
Wednesday’s 95% to 97% inhibition on human lung testing sets a new bar for antiviral therapies. The current best hope is Remdesivir which reduces hospital stays from 14 to 11 days. If Brilacidin is HALF as effective in human FDA trials as it is in the labs it will be by far the most effective and safe treatment. Based on Brilacidin’s multiple Phase 2 successes especially with ABSSSI, my bet is that human trials are a huge success. The antiviral, immuno/ anti-inflammatory and antimicrobial properties will make Brilacidin the top CV19 treatment.
Trying to negatively spin the NYT article is really grasping at straws but the criminals are between a rock and a hard place and they keep digging themselves a bigger hole. They have to somehow convince Longs to sell them shares. It will get progressively more challenging for them to maintain control over SP. It is going to be fun watching them lose control when grant funding and human FDA trials are announced. Hopefully they pay more than just a financial loss. IMO the squeeze won’t take place in a big way until $5 +/share. If they tried covering their 60-200M naked shares sub-dollar, the supply/demand imbalance would skyrocket SP. The criminals are in a pay me now or pay me later box.
“But the shift in strategy also shows that the administration is backing away from the relatively modest funding it has provided so far for treatments that address the severe lung ailments, while CONTINUING support for ANTIVIRAL therapies that could treat people earlier in the course of the disease.”
Wednesday’s 95% to 97% inhibition on human lung testing sets a new bar for antiviral therapies. The current best hope is Remdesivir which reduces hospital stays from 14 to 11 days. If Brilacidin is HALF as effective in human FDA trials as it is in the labs it will be by far the most effective and safe treatment. Based on Brilacidin’s multiple Phase 2 successes especially with ABSSSI, my bet is that human trials are a huge success. The antiviral, immuno/ anti-inflammatory and antimicrobial properties will make Brilacidin the top CV19 treatment.
Trying to negatively spin the NYT article is really grasping at straws but the criminals are between a rock and a hard place and they keep digging themselves a bigger hole. They have to somehow convince Longs to sell them shares. It will get progressively more challenging for them to maintain control over SP. It is going to be fun watching them lose control when grant funding and human FDA trials are announced. Hopefully they pay more than just a financial loss. IMO the squeeze won’t take place in a big way until $5 +/share. If they tried covering their 60-200M naked shares sub-dollar, the supply/demand imbalance would skyrocket SP. The criminals are in a pay me now or pay me later box.
(12)
(0)Scroll down for more posts ▼
